# Intravitreal Faricimab in Patients With Refractory Macular Edema

> **NCT07093385** · PHASE2 · COMPLETED · sponsor: **University of Baghdad** · enrollment: 43 (actual)

## Conditions studied

- Age-Related Macular Degeneration

## Interventions

- **DRUG:** Faricimab Injection

## Key facts

- **NCT ID:** NCT07093385
- **Lead sponsor:** University of Baghdad
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-09-10
- **Primary completion:** 2025-06-01
- **Final completion:** 2025-07-01
- **Target enrollment:** 43 (ACTUAL)
- **Last updated:** 2025-07-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07093385

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07093385, "Intravitreal Faricimab in Patients With Refractory Macular Edema". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07093385. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*